|
**Overview**: HHH Syndrome Panel**Introduction**: The HHH Syndrome Panel is a diagnostic tool designed to screen for HHH (hyperornithinemia-hyperammonemia-homocitrullinuria) syndrome using whole blood samples. In India, HHH syndrome (SLC25A15 mutations) is a rare urea cycle disorder (~1 in 1,000,000), presenting in childhood with episodic hyperammonemia, neurological symptoms (ataxia, spasticity), and chronic liver dysfunction. High morbidity from underdiagnosis in rural/low-SES children with recurrent vomiting, coma, or developmental delay, limited metabolic labs, delayed protein restriction/citrulline supplementation leading to brain damage or death. Per molecular pathology practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs PCR for SLC25A15 mutations and measures ornithine, ammonia, homocitrulline levels over 1-2 days with high accuracy, valuable for confirming diagnosis in suspected urea cycle disorders. This diagnostic falls under genetic disorder screening and targets children with hyperammonemia or neurological regression, addressing accurate detection to guide dietary management and monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing metabolic disorder burden. Its whole blood-based approach ensures reliable biochemical/genetic analysis.**Other Names**: HHH Syndrome Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: SLC25A15 testing standard; in India, used in metabolic clinics.**Purpose**: The test assesses 4 parameters including ornithine levels to guide HHH syndrome screening, detect biochemical/genetic abnormalities, inform diet.**Test Parameters**: 1. Ornithine Levels, 2. Ammonia Levels, 3. Homocitrulline Levels, 4. SLC25A15 Mutation.**Pretest Condition**: No fasting required; patients should report episodic vomiting or neurological symptoms.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for analysis).**Medical History**: Patients should provide details on hyperammonemic episodes, developmental delay.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed HHH including brain damage, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR and biochemical assay by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or dietary influence can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated ornithine/ammonia/homocitrulline with mutation confirms HHH, necessitating specialist input.**Specialist Consultation**: Pediatric metabolic specialists should be consulted for management.**Additional Supporting Tests**: Plasma amino acids, urine orotic acid for confirmation.**Test Limitations**: May miss rare mutations; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Metabolic Studies India 2023. |
